Gilead Sciences

Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced
Gilead cuts 7% of staff at Kite Pharma unit as 'refreshed business strategy' introduced
Fierce Pharma
Kite Pharma
Gilead Sciences
layoffs
Flag link:
Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash
Gilead’s Kite Expands Arcellx Pact with $285M Equity Investment, Upfront Cash
BioSpace
Gilead Sciences
Kite Pharma
Arcellx
CART-ddBCMA
lymphoma
Flag link:
Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat
Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat
Investors Business Daily
Gilead Sciences
earnings
Veklury
Flag link:
Gilead Sciences and Arcus Biosciences report cancer trial data
Gilead Sciences and Arcus Biosciences report cancer trial data
Clinical Trials Arena
Gilead Sciences
Arcus Biosciences
domvanalimab
zimberelimab
upper GI cancers
clinical trials
Flag link:
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
Flag link:
Gilead plans European trial of twice-yearly HIV PrEP drug
Gilead plans European trial of twice-yearly HIV PrEP drug
Pharmaphorum
Gilead Sciences
clinical trials
HIV
PrEP
Sunlenca
Europe
Flag link:
Gilead pays $100M for first dibs on all Assembly Bio assets, bolting antiviral engine to its R&D group
Gilead pays $100M for first dibs on all Assembly Bio assets, bolting antiviral engine to its R&D group
Fierce Biotech
Gilead Sciences
Assembly Biosciences
antivirals
hepatitis B
Flag link:
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
Gilead Axes Phase III Magrolimab Trial Based on Disappointing Data
BioSpace
Gilead Sciences
magrolimab
clinical trials
blood cancers
Flag link:
Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case
Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
HIV
legal
antitrust
Flag link:
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
Clinical Trials Arena
Gilead Sciences
Trodelvy
TROP-2
non-small cell lung cancer
Flag link:
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Clinical Trials Arena
Gilead Sciences
Kite Pharma
Yescarta
clinical trials
CAR-T
relapsed or refractory large B-cell lymphoma
Flag link:
Gilead unveils promising data from trial of combo therapy for lung cancer
Gilead unveils promising data from trial of combo therapy for lung cancer
Clinical Trials Arena
Gilead Sciences
Trodelvy
metastatic non-small cell lung cancer
Flag link:
Gilead-backed study warns IRA price negotiations could hit R&D harder than expected
Gilead-backed study warns IRA price negotiations could hit R&D harder than expected
Fierce Biotech
Gilead Sciences
Inflation Reduction Act
R&D
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Fierce Biotech
Gilead Sciences
MDS
magrolimab
clinical trials
AML
Flag link:
Gilead antibody drug shows signs of potential in early lung cancer
Gilead antibody drug shows signs of potential in early lung cancer
BioPharma Dive
Gilead Sciences
Trodelvy
Merck
Keytruda
lung cancer
Flag link:
Gilead, Tentarix collab to develop cancer, inflammatory disease therapies
Gilead, Tentarix collab to develop cancer, inflammatory disease therapies
Medical Marketing and Media
Gilead Sciences
Tentarix Biotherapeutics
cancer
inflammatory disease
Flag link:
Gilead inks $66M+ deal with Tentarix in oncology, inflammatory diseases
Gilead inks $66M+ deal with Tentarix in oncology, inflammatory diseases
Fierce Biotech
Tentarix Biotherapeutics
Gilead Sciences
oncology
inflammatory disease
Flag link:
FDA lifts clinical hold on Gilead's CAR-T as Arcellx sheds light on reason for patient death
FDA lifts clinical hold on Gilead's CAR-T as Arcellx sheds light on reason for patient death
Fierce Biotech
Gilead Sciences
Arcellx
CAR-T
cell therapy
FDA
Flag link:
ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
ALX follows Gilead in axing CD47 blood cancer trials as data disappoint
Fierce Biotech
Gilead Sciences
ALX Oncology
blood cancer
clinical trials
anti-CD47
evorpacept
Flag link:

Pages